Core Viewpoint - Amgen's stock has underperformed compared to the broader market and the Medical sector, with upcoming earnings expected to show a decline in EPS but an increase in revenue [1][2]. Group 1: Stock Performance - Amgen closed at $305.02, reflecting a -0.22% change from the previous day, which is slightly better than the S&P 500's loss of 0.11% [1]. - Over the last month, Amgen's shares decreased by 2.29%, while the Medical sector gained 4.12% and the S&P 500 gained 3.51% [1]. Group 2: Earnings Estimates - The upcoming EPS for Amgen is projected at $4.86, indicating a 2.8% decline compared to the same quarter last year [1]. - Revenue for the upcoming quarter is estimated at $8.27 billion, representing an 18.34% increase from the prior-year quarter [1]. - For the entire fiscal year, earnings are projected at $19.47 per share and revenue at $32.98 billion, reflecting changes of +4.4% and +17.01% respectively from the prior year [1]. Group 3: Analyst Estimates and Valuation - Recent analyst estimate revisions for Amgen have shown a 0.06% increase in the Zacks Consensus EPS estimate over the past month [2]. - Amgen currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook based on analyst estimates [2]. - The Forward P/E ratio for Amgen is 15.7, which is lower than the industry average of 22.87, suggesting that Amgen is trading at a discount [3]. - Amgen's PEG ratio stands at 2.76, compared to the industry average of 2.12, indicating a higher expected earnings growth rate relative to its price [3]. - The Medical - Biomedical and Genetics industry, which includes Amgen, has a Zacks Industry Rank of 83, placing it in the top 33% of over 250 industries [3].

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this world's largest biotech drugmaker have returned -2.3%, compared to the Zacks S&P 500 composite's +3.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Amgen falls in, has gained 2.2%. The key question now is: What could be the stock's future direction ...

Amgen (AMGN) announced positive results from the phase III MITIGATE study, which evaluated its rare disease drug Uplizna (inebilizumab) for treating Immunoglobulin G4-related disease (IgG4-RD), a rare inflammatory condition.The MITIGATE study achieved its primary endpoint — patients treated with Uplizna over a 52-week period showed a statistically significant 87% reduction in the risk of IgG4-RD flare when compared with a placebo. The study also achieved key secondary endpoints, which include annualized fla ...

THOUSAND OAKS, Calif., June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45th Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, June 10, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the ...

Data Show a Statistically Significant 87% Reduction in IgG4-RD Flares, With Primary and All Key Secondary Endpoints MetFirst Randomized, Placebo-Controlled Trial to Demonstrate Benefit in IgG4-RDTHOUSAND OAKS, Calif., June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from its randomized, double-blind, multicenter, placebo-controlled Phase 3 clinical trial (NCT04540497) evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of Immunoglobul ...

AltaybIntroduction I imagine the dream of every Formula 1 driver is to win a Championship, the dream of every football player is to win the Super Bowl, and the dream of every politician to eventually call the Oval Office their workplace. Healthcare/biotech investors probably dream of their companies launching a product that is as successful as the latest weight loss drugs from Eli Lilly (LLY) and Novo Nordisk (NVO), whose shares have gained 611% and 471% over the past five years alone, respectively. Dat ...

There's probably a big enough pie here for everyone to get a slice.Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and Wegovy, billions in new revenue inflows are assured in the near term.But those two juggernauts aren't the only competitors looking to get a slice of the action -- they're just the first. Three aspiring contenders are raring to go, and they might even be able to claim the crown one day. Let's take a look at each to see if an ...

The Amgen of 2027 could be much be larger than some investors expect.If you're looking for an investment in the pharmaceutical sector and you don't already own shares of Amgen (AMGN -1.85%), it might be worth considering a purchase. The company's development of highly technological cancer therapies is almost certain to expand over time, and its pipeline is packed with candidates for next-generation medicines. Many of those candidates will likely get their shot at approval by regulators.So let's see where Am ...

Data From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell EngagersOverall Survival Data from Phase 3 LUMAKRAS® (sotorasib) Plus Vectibix® (panitumumab) in Metastatic Colorectal Cancer Accepted as Late-Breaking Oral PresentationTHOUSAND OAKS, Calif., May 28, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology portfolio at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking plac ...

The gold rush for obesity medications just got a bit more intense.With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen's (AMGN -0.21%) latest attempt to develop a therapy for obesity is looking like it could be a contender for the crown that's currently jointly held by the likes of Eli Lilly (LLY -0.13%) and Novo Nordisk (NVO 0.35%). Though it won't be competing with those two heavyweights directly until it finishes the clinical trials process, which co ...